Dupixent (dupilumab) - Sanofi, Regeneron
Erythroderma Associated with Phenotype Shift from Atopic Dermatitis to Eczema–Psoriasis Overlap Following Dupilumab Exposure (ACAAI 2026) - Oct 28, 2026 - Abstract #M063; Pres time: Nov 13, 2026; 02:55 PM - 06:00 PM; Location: Phoenix Convention Center • North Halls 4–6 (Lower Level); Monitor 4; No abstract available 
Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Psoriasis
https://annualmeeting.acaai.org/2026/submit_abstract.cfm
 
Oct 28, 2026
 
Prev Next